Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06556862
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-05
Brief Title:
Exploration of Dalpiciclib Tucidinostat in HRHER2- Advanced Breast Cancer After Failure of CDK46 Inhibitor
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Exploration of Dalpiciclib Tucidinostat in HRHER2- Advanced Breast Cancer After Failure of CDK46 Inhibitor a Phase II Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase II study to explore the efficacy and safety of dalpiciclib tucidinostat in HRHER2- advanced breast cancer after the failure of CDK46 inhibitor therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None